Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.
Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.
X4 Pharmaceuticals (Nasdaq: XFOR) provided a financial update for Q4 and full year 2020, reporting a net loss of $62.1 million, up from $52.8 million in 2019. The company focuses on its lead candidate, mavorixafor, currently undergoing Phase 3 trials for WHIM syndrome and Phase 1b trials for Waldenström’s and SCN. X4 expects to complete enrollment in the WHIM trial in 2021, with data expected in 2022. The company also received Fast Track and Rare Pediatric Designations for mavorixafor from the FDA to address unmet needs in WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to report its financial results for Q4 and the full year ended December 31, 2020, on March 4, 2021. The announcement includes insights into recent business highlights and will be followed by a conference call at 8:30 a.m. ET. The company specializes in therapies targeting the CXCR4 pathway, with its lead candidate mavorixafor undergoing various clinical trials. X4 aims to address rare diseases and those with limited treatment options, leveraging its expertise at its facilities in Boston and Vienna.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will participate in the B. Riley Oncology Institutional Investor Conference on January 20, 2021, at 11:00 AM ET. The event includes a fireside chat and one-on-one investor meetings. Due to audience limitations, advance registration is required. An archived webcast will be available on the X4 Pharmaceuticals website for 90 days post-event. The company focuses on developing therapies targeting CXCR4 pathway dysfunction, with its lead candidate mavorixafor currently in Phase 3 and Phase 1b clinical trials for various conditions.
X4 Pharmaceuticals (Nasdaq: XFOR) has announced its participation in the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The company's management will present on their innovative therapies targeting CXCR4 pathway dysfunction. An on-demand webcast of the presentation will be accessible on X4's investor website starting January 11, and it will remain available for about 90 days post-conference. X4 is focused on rare diseases with limited treatment options, and its lead candidate, mavorixafor, is currently in pivotal clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on January 4, 2021, that its Board of Directors granted inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. This includes options to purchase 156,050 shares at an exercise price of $6.43, equal to the stock's closing price on November 30, 2020. The options will vest over four years, contingent on continued employment. X4 focuses on developing therapies targeting diseases from CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, in advanced clinical trials for conditions like WHIM syndrome.
X4 Pharmaceuticals has appointed Diego Cadavid, M.D. as its new Chief Medical Officer. Dr. Cadavid will lead the strategy and execution of the company's clinical development programs. His expertise in advancing therapies for rare and immunological diseases is expected to positively influence ongoing programs, including the Phase 3 trial of mavorixafor for WHIM syndrome. With over 22 years of experience, including roles at Fulcrum Therapeutics and Biogen, Dr. Cadavid aims to leverage his skills to further develop mavorixafor and other preclinical candidates.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its lead asset, mavorixafor, has received Rare Pediatric Disease (RPD) Designation from the FDA for treating WHIM syndrome, a rare primary immunodeficiency disease. This designation highlights the significant unmet medical need for effective therapies for WHIM patients, especially children who face serious infections. Mavorixafor is under investigation in a global Phase 3 clinical trial, 4WHIM, with anticipated results in 2022, aiming to provide a novel treatment option for over 3,500 diagnosed undiagnosed patients in the U.S.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on November 30, 2020, that its Compensation Committee granted an inducement award to new employees under the 2019 Inducement Equity Incentive Plan. This includes options to purchase 125,950 shares of common stock at $6.60 each, the closing price on that day. Options will vest over four years, with 25% vesting after the first year. X4 focuses on therapies targeting CXCR4 pathway dysfunction, with its lead candidate mavorixafor undergoing clinical trials for various conditions, including WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 8:40 AM ET. This event will feature a fireside chat and one-on-one investor meetings. A live webcast of the chat will be available on X4's investor website and archived for 90 days. X4 specializes in developing therapies targeting the CXCR4 pathway, including its lead candidate, mavorixafor, currently in Phase 3 trials for treating WHIM syndrome and other rare diseases.
X4 Pharmaceuticals (XFOR) reported Q3 2020 financial results, revealing a net loss of $17.4 million, slightly improved from $17.7 million in Q3 2019. The company highlighted significant Phase 2 data for mavorixafor in WHIM syndrome published in 'Blood' and received FDA Fast Track Designation for the drug. The leadership team was strengthened with the appointment of Art Taveras as CSO and Alison Lawton to the Board of Directors. As of September 30, 2020, cash and equivalents stood at $90.7 million, which is expected to fund operations into early 2022.
